Phase 2 Open-label Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival (PFS) rate at 4 months
4 months
No
MD
Study Director
Amgen
Australia: Human Research Ethics Committee
20080580
NCT00872014
August 2009
June 2015
Name | Location |
---|